- Home
- PRFX vs HSDT Comparison
PRFX vs HSDT Comparison
Compare PRFX & HSDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- HSDT
- Stock Information
- Founded
- PRFX 2007
- HSDT N/A
- Country
- PRFX Israel
- HSDT United States
- Employees
- PRFX N/A
- HSDT N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PRFX Health Care
- HSDT Health Care
- Exchange
- PRFX Nasdaq
- HSDT Nasdaq
- Market Cap
- PRFX 2.9M
- HSDT 2.5M
- IPO Year
- PRFX 2020
- HSDT N/A
- Fundamental
- Price
- PRFX $1.40
- HSDT $7.35
- Analyst Decision
- PRFX Hold
- HSDT Hold
- Analyst Count
- PRFX 1
- HSDT 1
- Target Price
- PRFX N/A
- HSDT N/A
- AVG Volume (30 Days)
- PRFX 326.0K
- HSDT 206.0K
- Earning Date
- PRFX 08-14-2025
- HSDT 08-11-2025
- Dividend Yield
- PRFX N/A
- HSDT N/A
- EPS Growth
- PRFX N/A
- HSDT N/A
- EPS
- PRFX N/A
- HSDT N/A
- Revenue
- PRFX N/A
- HSDT $434,000.00
- Revenue This Year
- PRFX N/A
- HSDT N/A
- Revenue Next Year
- PRFX N/A
- HSDT $75.13
- P/E Ratio
- PRFX N/A
- HSDT N/A
- Revenue Growth
- PRFX N/A
- HSDT N/A
- 52 Week Low
- PRFX $1.25
- HSDT $7.21
- 52 Week High
- PRFX $16.63
- HSDT $1,200.00
- Technical
- Relative Strength Index (RSI)
- PRFX 35.72
- HSDT 21.13
- Support Level
- PRFX $1.25
- HSDT $8.21
- Resistance Level
- PRFX $1.44
- HSDT $8.78
- Average True Range (ATR)
- PRFX 0.10
- HSDT 1.44
- MACD
- PRFX 0.01
- HSDT 6.61
- Stochastic Oscillator
- PRFX 50.00
- HSDT 1.66
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About HSDT Helius Medical Technologies Inc. (DE)
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.